Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Clinical Trials Market 

5.1. COVID-19 Landscape: US Clinical Trials Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US Clinical Trials Market, By Phase

8.1. US Clinical Trials Market, by Phase, 2022-2032

8.1.1 Phase I

8.1.1.1. Market Revenue and Forecast (2022-2032)

8.1.2. Phase II

8.1.2.1. Market Revenue and Forecast (2022-2032)

8.1.3. Phase III

8.1.3.1. Market Revenue and Forecast (2022-2032)

8.1.4. Phase IV

8.1.4.1. Market Revenue and Forecast (2022-2032)

Chapter 9. US Clinical Trials Market, By Study Design

9.1. US Clinical Trials Market, by Study Design, 2022-2032

9.1.1. Interventional

9.1.1.1. Market Revenue and Forecast (2022-2032)

9.1.2. Observational

9.1.2.1. Market Revenue and Forecast (2022-2032)

Chapter 10. US Clinical Trials Market, By Indication 

10.1. US Clinical Trials Market, by Indication, 2022-2032

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2022-2032)

10.1.2. Autoimmune

10.1.2.1. Market Revenue and Forecast (2022-2032)

10.1.3. Pain Management

10.1.3.1. Market Revenue and Forecast (2022-2032)

10.1.4. CNS Conditions

10.1.4.1. Market Revenue and Forecast (2022-2032)

10.1.5. Obesity

10.1.5.1. Market Revenue and Forecast (2022-2032)

10.1.6. Cardiovascular

10.1.6.1. Market Revenue and Forecast (2022-2032)

10.1.7. Diabetes

10.1.7.1. Market Revenue and Forecast (2022-2032)

Chapter 11. Global US Clinical Trials Market, Regional Estimates and Trend Forecast

11.1. U.S.

11.1.1. Market Revenue and Forecast, by Phase (2022-2032)

11.1.2. Market Revenue and Forecast, by Study Design (2022-2032)

11.1.3. Market Revenue and Forecast, by Indication (2022-2032)

Chapter 12. Company Profiles

12.1. Parexel International Corp.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Charles River Laboratory

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. PRA Health Sciences

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Wuxi AppTec

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Eli Lilly and Company

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Novo Nordisk A/S

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Clinipace

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Omnicare

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Kendle

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Chiltern

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms